{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:12:46Z","timestamp":1793373166139,"version":"4.5.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Haplo-identical transplant with posttransplant cyclophosphamide (haplo) and umbilical cord blood transplant supported by third-party CD34 cells (haplo-cord) are competing approaches to alternative donor transplant. We compared, in adults younger than age 60 years, the outcomes of 170 haplo at 1 institution with that of 137 haplo-cord at 2 other institutions. All received reduced intensity conditioning with fludarabine and melphalan \u00b1 total body irradiation. GVHD prophylaxis for haplo consisted of cyclophosphamide, tacrolimus, and mycophenolate, whereas haplo-cord received antithymocyte globulin, tacrolimus, and mycophenolate. Haplo transplant used mostly bone marrow, and peripheral blood stem cells were used in haplo-cord transplants. Haplo-cord were older and had more advanced disease. Haplo-cord hastened median time to neutrophil (11 vs 18 days, P = .001) and platelet recovery (22 vs 25 days, P = .03). At 4 years, overall survival (OS) was 50% for haplo-cord vs 49% for haplo. Progression-free survival (PFS) was 40% for haplo-cord vs 45% for haplo. In multivariate analysis, the disease risk index was significant for OS (hazard ratio, 1.8; 95% confidence interval, 1.48-2.17; P = .00) and PFS. Total body irradiation was associated with decreased recurrence and improved PFS, age &amp;gt;40 with increased nonrelapse mortality. The type of transplant had no effect on OS, PFS, relapse, or nonrelapse mortality. Cumulative incidence of grade 2-4 acute graft-versus-host disease (GVHD) by day 100 was 16% after haplo-cord vs 33% after haplo (P &amp;lt; .0001), but grade 3-4 GVHD was similar. Chronic GVHD at 1 year was 4% after haplo-cord vs 16% after haplo (P &amp;lt; .0001). Haplo or haplo-cord results in similar and encouraging outcomes. Haplo-cord is associated with more rapid neutrophil and platelet recovery and lower acute and chronic GVHD. Institutional review board authorization for this retrospective study was obtained at each institution. Some patients participated in trials registered at www.clinicaltrials.gov as #NCT01810588 and NCT 01050946.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000200","type":"journal-article","created":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T16:49:01Z","timestamp":1560962941000},"page":"1858-1867","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":37,"title":["Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-6211","authenticated-orcid":false,"given":"Koen","family":"van Besien","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Chicago, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Guarneri","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Chicago, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6033-0747","authenticated-orcid":false,"given":"Tsiporah","family":"Shore","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3190-7807","authenticated-orcid":false,"given":"Hongtao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Chicago, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian A.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer A.","family":"Srour","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Chicago, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"issue":"8","key":"2020021109110916400_B1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020021109110916400_B2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.bbmt.2017.03.001","article-title":"Prospective evaluation of unrelated donor cord blood and haploidentical donor access reveals graft availability varies by patient ancestry: practical implications for donor selection","volume":"23","author":"Kosuri","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020021109110916400_B3","doi-asserted-by":"crossref","first-page":"e974393","DOI":"10.4161\/2162402X.2014.974393","article-title":"Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent","volume":"4","author":"Kanakry","year":"2015","journal-title":"OncoImmunology"},{"issue":"5","key":"2020021109110916400_B4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/leu.2014.314","article-title":"Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation","volume":"29","author":"Crucitti","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"2020021109110916400_B5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2020021109110916400_B6","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.bbmt.2015.07.029","article-title":"High disease-free survival with enhanced protection against relapse after double-unit cord blood transplantation when compared with T cell-depleted unrelated donor transplantation in patients with acute leukemia and chronic myelogenous leukemia","volume":"21","author":"Ponce","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020021109110916400_B7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10428194.2016.1190970","article-title":"Cord blood chimerism and relapse after haplo-cord transplantation","volume":"58","author":"van Besien","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2020021109110916400_B8","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1207285","article-title":"Cord-blood engraftment with ex vivo mesenchymal-cell coculture","volume":"367","author":"de Lima","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"2020021109110916400_B9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.seminhematol.2016.07.004","article-title":"Haploidentical cord transplantation-The best of both worlds","volume":"53","author":"van Besien","year":"2016","journal-title":"Semin Hematol"},{"issue":"10","key":"2020021109110916400_B10","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.bbmt.2015.06.001","article-title":"Sufficient immunosuppression with thymoglobulin is essential for a successful haplo-myeloid bridge in haploidentical-cord blood transplantation","volume":"21","author":"Lindemans","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"2020021109110916400_B11","article-title":"Cord blood transplants supported by unrelated donor CD34 progenitor cells [abstract]","volume":"132","author":"Gomez-Arteaga","year":"2018","journal-title":"Blood"},{"issue":"24","key":"2020021109110916400_B12","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1182\/blood-2011-08-372508","article-title":"Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions","volume":"118","author":"Liu","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2020021109110916400_B13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation [published correction appears in Bone Marrow Transplant. 2019;54(5):784]","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020021109110916400_B14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","article-title":"Classification systems for chronic graft-versus-host disease","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2020021109110916400_B15","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2020021109110916400_B16","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/bmt.2017.36","article-title":"Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML","volume":"52","author":"Kwon","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020021109110916400_B17","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1097\/TP.0000000000001538","article-title":"The addition of low-dose total body irradiation to fludarabine and melphalan conditioning in haplocord transplantation for high-risk hematological malignancies","volume":"101","author":"Choe","year":"2017","journal-title":"Transplantation"},{"issue":"3","key":"2020021109110916400_B18","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/j.bbmt.2017.12.303","article-title":"Cord haploidentical non-in vitro T cell depletion allogeneic hematopoietic stem cell transplantation reduces relapse of refractory acute leukemia","volume":"24","author":"Wang","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020021109110916400_B19","first-page":"1","article-title":"Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation","author":"van Rood","year":"2012","journal-title":"Proc Natl Acad Sciences U S A"},{"key":"2020021109110916400_B20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3324\/haematol.2015.138594","article-title":"Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and survival free of progression and GVHD (GRFS)","volume":"101","author":"van Besien","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"2020021109110916400_B21","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2020021109110916400_B22","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.bbmt.2018.07.012","article-title":"Multifaceted burden of chronic graft-versus-host disease","volume":"24","author":"Radojcic","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020021109110916400_B23","first-page":"1","article-title":"Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk","author":"Van Besien","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2020021109110916400_B24","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3109\/10428194.2012.739688","article-title":"Immune reconstitution after combined haploidentical and umbilical cord blood transplant","volume":"54","author":"Jain","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2020021109110916400_B25","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020021109110916400_B26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2015.133","article-title":"Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients","volume":"50","author":"Yew","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"2020021109110916400_B27","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1182\/blood-2011-08-372508","article-title":"Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions","volume":"118","author":"Liu","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2020021109110916400_B28","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbmt.2009.01.011","article-title":"Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications","volume":"15","author":"Majhail","year":"2009","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/12\/1858\/1555094\/advancesadv2019000200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/12\/1858\/1555094\/advancesadv2019000200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:47:58Z","timestamp":1581414478000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/12\/1858\/261348\/Haploidentical-vs-haplocord-transplant-in-adults"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,19]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000200","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,19]]}}}